Haval Shirwan, PhD
Department of Child Health and Microbiology and Immunology, NextGen Precision Health, University of Missouri, Columbia, MO, USA
Research Interests: Modulation of immune system for the treatment of immune-based disorders with particular focus on autoimmune diseases, transplantation, and cancer immunoprevention/therapy
Dr. Shirwan is Professor of Child Health and Molecular Microbiology and Immunology in the School of Medicine and a NextGen Precision Health faculty member, University of Missouri-Columbia, MO. He obtained his PhD from the University of California in Santa Barbara, CA, and performed postdoctoral studies at the California Institute of Technology, Pasadena, CA. Before relocating to the University of Missouri-Columbia in 2020, Dr. Shirwan served on the Faculty of various academic institutions in the United States, including Cedars-Sinai Medical Center, Los Angeles, CA, Alleghany University of Health Science, Philadelphia, PA, University of Louisville, Louisville, KY.
Dr. Shirwan pioneered the concept of transient and positional display of immunological ligands on the surface of cells and tissues as a safe, practical, and effective alternative to gene therapy for localized immunomodulation with applications to transplantation, autoimmunity, and cancer immunoprevention and immunotherapy.
Dr. Shirwan is an inventor with 25 issued patents, founder/co-founder of 3 biotech startups, widely published, and organized and lectured at numerous national/international conferences. He has continuously been funded by federal and non-federal funding agencies and serves on the editorial board of various scientific journals.
Editorial Board
Terms of Appointment: June 2018 - June 2020; February 2021 - January 2023; February 2023 - January 2025